84 related articles for article (PubMed ID: 3492432)
1. Mechanism of in vitro antitumor effects of interleukin 1 (IL 1).
Endo Y; Matsushima K; Oppenheim JJ
Immunobiology; 1986 Sep; 172(3-5):316-22. PubMed ID: 3492432
[TBL] [Abstract][Full Text] [Related]
2. Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor.
Endo Y; Matsushima K; Onozaki K; Oppenheim JJ
J Immunol; 1988 Oct; 141(7):2342-8. PubMed ID: 2971724
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both.
Ichinose Y; Bakouche O; Tsao JY; Fidler IJ
J Immunol; 1988 Jul; 141(2):512-8. PubMed ID: 3260254
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
5. Human interleukin 1 is a cytocidal factor for several tumor cell lines.
Onozaki K; Matsushima K; Aggarwal BB; Oppenheim JJ
J Immunol; 1985 Dec; 135(6):3962-8. PubMed ID: 2415593
[TBL] [Abstract][Full Text] [Related]
6. Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity.
Onozaki K; Matsushima K; Kleinerman ES; Saito T; Oppenheim JJ
J Immunol; 1985 Jul; 135(1):314-20. PubMed ID: 3873493
[TBL] [Abstract][Full Text] [Related]
7. Role of putrescine in interleukin 1 beta production in human histiocytic lymphoma cell line U937.
Tahara H; Otani S; Matsui-Yuasa I; Koyama H; Nishizawa Y; Morisawa S; Morii H
J Cell Physiol; 1991 May; 147(2):199-207. PubMed ID: 2040654
[TBL] [Abstract][Full Text] [Related]
8. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal cells and squamous carcinoma cells synthesize a cytokine that augments natural killer cell activity.
Luger TA; Uchida A; Köck A; Colot M; Micksche M
J Immunol; 1985 Apr; 134(4):2477-83. PubMed ID: 3882831
[TBL] [Abstract][Full Text] [Related]
10. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
Cancer Res; 1991 Feb; 51(3):769-74. PubMed ID: 1824825
[TBL] [Abstract][Full Text] [Related]
11. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines.
Morinaga Y; Suzuki H; Takatsuki F; Akiyama Y; Taniyama T; Matsushima K; Onozaki K
J Immunol; 1989 Dec; 143(11):3538-42. PubMed ID: 2584706
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
Gan X; Zhang L; Solomon GF; Bonavida B
Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
Utsugi T; Sone S
J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
[TBL] [Abstract][Full Text] [Related]
14. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
[TBL] [Abstract][Full Text] [Related]
15. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
Colotta F; Peri G; Villa A; Mantovani A
J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
[TBL] [Abstract][Full Text] [Related]
16. Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells.
Lachman LB; Dinarello CA; Llansa ND; Fidler IJ
J Immunol; 1986 Apr; 136(8):3098-102. PubMed ID: 3485680
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2, monocyte adherence and interleukin-1 in the regulation of human natural killer cell activity by monocytes.
Bloom ET; Babbitt JT
Nat Immun Cell Growth Regul; 1990; 9(1):36-48. PubMed ID: 2139495
[TBL] [Abstract][Full Text] [Related]
18. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
[TBL] [Abstract][Full Text] [Related]
19. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells.
Mimnaugh EG; Monti E; Sebers S; Stetler-Stevenson M; Sinha BK
Oncol Res; 1992; 4(10):401-12. PubMed ID: 1292755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
